



## MGI empowers partners like Gene+ to deliver oncology solutions

## MGI Tech Co., Ltd.

MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision healthcare and




other relevant areas. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.

## Beijing GenePlus Technology Co., Ltd.


Beijing GenePlus Technology Co., Ltd (referred to as Gene+) was founded in 2015 and has since equipped next-generation sequencing (NGS) clinical laboratories and genetic institutes in Beijing, Suzhou and Shenzhen. Gene+ is a leading supplier for oncology and precision medicine in China. The Gene+ all-in-one solution utilizing MGI's DNBSEQ platforms in Oncology has already been deployed in more than 30 key hospitals in China and is becoming a leader in the clinical application of NGS.

Together with MGI Gene+ has achieved:










## The consistency of detected mutations between automated library construction samples by SP 100 and conventional library construction samples is 100%

Available assays include a Oncology 59-Gene Variant Assay and a Oncology Multi-Gene Variant Assay (1021-Gene) which have been validated on the DNBSEQ-G400\* using HotMPS sequencing chemistry.



<sup>\*</sup> This sequencer is only available in selected countries, and its software has been specially configured to be used in conjunction with MGI's HotMPS sequencing reagents exclusively.